CSF1R
ENSG00000182578
Target class
Kinase
Chromosome
5
Approved drugs
7
Clinical candidates (approved and in development)
20
- Approved drugs
- 7
- ClinGen gene-disease validity
- Definitive
- Clinical candidates (approved and in development)
- 20
- Chemical probe available
- Yes
- Target name
- CSF1R
- Gene name
- Colony stimulating factor 1 receptor
- Gene symbol
- CSF1R
- Previous gene symbols
- FMS
- Protein name
- Macrophage colony-stimulating factor 1 receptor (CSF-1 receptor) (CSF-1-R) (CSF-1R) (M-CSF-R) (EC 2.7.10.1) (Proto-oncogene c-Fms) (CD antigen CD115)
- C-FMS
- CSFR
- CD115
- Gene biotype
- Protein coding
- Gene family
- Receptor tyrosine kinases|CD molecules|Immunoglobulin like domain containing
- Target class
- Kinase
- Target type
- Human gene
- Tissues expressed in
- 52
- Protein localisation evidence grade
- Supported
- Highest tissue expression
- 206.87
- Tissue specificity (Gini)
- 0.491
- Tissue specificity (tau)
- 0.928
- KEGG gene identifiers
- hsa:1436
- Protein interaction confidence
- 0.802641
- Protein interaction partners
- 117
- R-HSA-449836
- R-HSA-8853884
- R-HSA-9680350
- End position
- 150113372
- Start position
- 150053291
- Chromosome
- 5
- Strand
- Reverse
- Cell membrane
- Single-pass type I membrane protein.
- Plasma membrane
- Vesicles
- Tissue specificity (tau)
- 0.927965
- Expression inequality (Gini)
- 0.491233
Expression in transcripts per million
- Spleen
- 206.87
- Nerve - Tibial
- 49.67
- Adipose - Subcutaneous
- 38.03
- Lung
- 37.92
- Adipose - Visceral (Omentum)
- 34.34
Expression in transcripts per million
- Spleen206.87
- Nerve - Tibial49.67
- Adipose - Subcutaneous38.03
- Lung37.92
- Adipose - Visceral (Omentum)34.34
- Brain - Spinal cord (cervical c-1)33.67
- Artery - Coronary31.88
- Small Intestine - Terminal Ileum29.82
- Artery - Aorta29.58
- Whole Blood29.54
- Adrenal Gland25.48
- Brain - Substantia nigra21.62
- Bladder19.15
- Colon - Sigmoid18.24
- Breast - Mammary Tissue17.39
- Brain - Hypothalamus17.07
- Fallopian Tube17.06
- Artery - Tibial17.04
- Colon - Transverse16.07
- Stomach16.06
- Cervix - Endocervix15.49
- Esophagus - Gastroesophageal Junction15.45
- Prostate15.22
- Esophagus - Muscularis14.69
- Minor Salivary Gland14.16
And 29 more, listed on the interactive page.
- GO:0001934
- GO:0006954
- GO:0007165
- GO:0008283
- GO:0008284
- GO:0008360
- GO:0010759
- GO:0018108
- GO:0019221
- GO:0030097
- GO:0030224
- GO:0030225
- GO:0032722
- GO:0036006
- GO:0045217
- GO:0046777
- GO:0060603
- GO:0061098
- GO:0120041
- GO:2000147
Cellular components
- GO:0005886
- GO:0004713
- GO:0005011
- GO:0005515
- GO:0019955
regulation of catalytic activity
Studies
- biochemical: NVS_ENZ_hCSF1R, is one of one assay component(s) measured or calculated from the NVS_ENZ_hCSF1R assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence and electrophoretic mobility shift technology.
Biological samples
- cell-free
Evidence source
Related records
Trials (895)
- (Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors
- (QuANTUM-R): An Open-label Study of Quizartinib Monotherapy vs. Salvage Chemotherapy in Acute Myeloid Leukemia (AML) Subjects Who Are FLT3-ITD Positive
- [18F]Fluciclatide-PET, Pazopanib and Paclitaxel in Ovarian Cancer
- 12 Week Patient Study in Neovascular Age-related Macular Degeneration (AMD)
- A Bioequivalence Study of Sunitinib Malate Capsules.
- A BIOmarker Driven Trial With Nivolumab and Ipilimumab or VEGFR tKi in Naïve Metastatic Kidney Cancer
- A Clinical Trial Assessing Efficacy and Safety of Sunitinib and Exemestane in Patients With ER [Estrogen Receptor] + and/or PgR [Progesterone Receptor] + Breast Cancer
- A Clinical Trial Comparing Efficacy And Safety Of Sunitinib And Capecitabine
- A Clinical Trial Comparing Efficacy And Safety Of Sunitinib Versus Placebo For TheTreatment Of Patients At High Risk Of Recurrent Renal Cell Cancer
- A Clinical Trial to Assess the Efficacy and Safety of the Combination of a Drug Call Quizartinib With Chemotherapy (FLAG-IDA) in Patients With Acute Myeloid Leukemia That Has Not Responded to the First Treatment or That Has Returned After the First Treatment
- A Combination Clinical Study of PLX3397 and Pembrolizumab To Treat Advanced Melanoma and Other Solid Tumors
- A Combination of Pazopanib and Carboplatin in Advanced Solid Malignancies
- A Comparison of Vorolanib Tablets Combined With Everolimus Versus Sunitinib in Patients With Advanced Renal Cell Carcinoma Who Have Progressed After Treatment With Immunotherapy Monotherapy or in Combination With TKI
- A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study.
- A CpG-methylation-based Assay for Stratifying Stage III Clear Cell Renal Cell Carcinoma of Receiving Adjuvant Treatment
- A Dose-Escalation Study of ENMD-2076 Administered Orally to Patients With Advanced Cancer
- A Long-term Study Evaluating Hepatotoxicity Associated With TURALIO™ (Pexidartinib) Treatment
- A Multi-center, Open-label Study of Oral ENMD-2076 for the Treatment of Patients With Advanced Fibrolamellar Carcinoma
- A Ph1b/2 Study of Axatilimab Monotherapy in Chinese Participants With Recurrent or Refractory cGVHD
- A Pharmacokinetic Study to Access How the Body Absorbs and Removes Linifanib in Male Patients With Advanced Solid Tumors.
Drugs (21)
- AMG-820 Macrophage colony stimulating factor receptor inhibitor
- ARRY-382 Macrophage colony stimulating factor receptor inhibitor
- Axatilimab Macrophage colony stimulating factor receptor inhibitor
- Cabiralizumab Macrophage colony stimulating factor receptor antagonist
- CT-1578 Macrophage colony stimulating factor receptor inhibitor
- Edicotinib Macrophage colony stimulating factor receptor inhibitor
- Emactuzumab Macrophage colony stimulating factor receptor inhibitor
- ENMD-2076 Macrophage colony stimulating factor receptor inhibitor
- IMC-CS4 Macrophage colony stimulating factor receptor inhibitor
- Linifanib Macrophage colony stimulating factor receptor inhibitor
- Pazopanib Macrophage colony stimulating factor receptor inhibitor
- Pazopanib hydrochloride Macrophage colony stimulating factor receptor inhibitor
- Pexidartinib Macrophage colony stimulating factor receptor inhibitor
- Pexidartinib hydrochloride Macrophage colony stimulating factor receptor inhibitor
- PLX-5622 Macrophage colony stimulating factor receptor inhibitor
- PLX-7486 Macrophage colony stimulating factor receptor inhibitor
- Quizartinib Macrophage colony stimulating factor receptor inhibitor
- Seralutinib Macrophage colony stimulating factor receptor inhibitor
- Sunitinib Macrophage colony stimulating factor receptor inhibitor
- Sunitinib malate Macrophage colony stimulating factor receptor inhibitor